Cholesterol efflux capacity and atherosclerosis

New England Journal of Medicine

Volumn 364, Issue 15, 2011, Pages 1473-

  Asleh, Rabea ^a   Levy, Andrew P ^a   Blum, Shany ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN; CHOLESTEROL; HEMOGLOBIN;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; DIABETES MELLITUS; DISEASE ASSOCIATION; GENE; HAPTOGLOBIN 2 GENE; HOMOZYGOSITY; HUMAN; LETTER; LIPOPROTEIN METABOLISM; NONHUMAN; OXIDATION; PRIORITY JOURNAL; TRANSGENIC MOUSE; VITAMIN SUPPLEMENTATION; CORONARY ARTERY DISEASE; GENETICS; GENOTYPE; METABOLISM; NOTE;

CHOLESTEROL; CORONARY ARTERY DISEASE; GENOTYPE; HAPTOGLOBINS; HEMOGLOBINS; HUMANS; LIPOPROTEINS, HDL;

EID: 84863752708     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Heinecke J. HDL and cardiovascular disease risk - time for a new approach? N Engl J Med 2011;364:170-1.
2. Levy AP, Asleh R, Blum S, et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 2010;12:293-304.
3. Asleh R, Blum S, Kalet-Litman S, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 2008;57:2794-800.
4. Blum S, Vardi M, Brown JB, et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics 2010;11:675-84.